10 Cheap Biotech Stocks to Invest in Now

8. United Therapeutics Corporation (NASDAQ:UTHR)

P/E Ratio: 15.56 

United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that specializes in treating infectious diseases, pediatric oncology, and uncommon, life-threatening illnesses, especially cardiovascular conditions like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company manufactures pharmaceutical drugs such as Adcirca (tadalafil) for PAH, Unituxin (dinutuximab) for high-risk neuroblastoma in pediatric oncology, and prostacyclin analogs (Remodulin, Tyvaso, Orenitram) for PAH and PH-ILD.

United Therapeutics Corporation (NASDAQ:UTHR) delivered impressive financial results for Q3 2024, positioning itself as a promising choice for investors interested in cheap biotech stocks to buy and affordable healthcare stocks. The company reported a 23% year-over-year revenue increase, reaching $748.9 million, largely driven by a 33% rise in Tyvaso sales, which totaled $433.8 million. Products like Orenitram and Unituxin also showed strong revenue gains, while Remodulin and Adcirca saw minor declines. Net income climbed 16% to $309.1 million, with diluted earnings per share rising 19% to $6.39. The robust performance was propelled by growing demand for pulmonary hypertension treatments, particularly Tyvaso. United Therapeutics Corporation (NASDAQ:UTHR) anticipates significant clinical and regulatory developments in 2025 to further support its expansion.

Analysts hold a consensus Moderate Buy rating on the stock. As of Q3 2024, 39 hedge funds held shares in the company as tracked by the Insider Monkey database. The largest shareholder in the company was VenBio Select Advisor with stakes worth $1.02 billion.